$0.59
-0.06 (-9.42%)
Open$0.64
Previous Close$0.65
Day High$0.66
Day Low$0.56
52W High$29.80
52W Low$0.33
Volume—
Avg Volume23.55M
Market Cap5.68M
P/E Ratio—
EPS$-14.33
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+691.2% upside
Current
$0.59
$0.59
Target
$4.68
$4.68
$2.81
$4.68 avg
$5.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 89.85M | 92.07M | 3.13M |
| Net Income | -72,144,543 | -66,533,547 | -134,676 |
| Profit Margin | -80.3% | -76.3% | -4.3% |
| EBITDA | -52,752,640 | -51,352,605 | -218,349 |
| Free Cash Flow | — | — | -122,296 |
| Rev Growth | -2.4% | -2.4% | +0.4% |
| Debt/Equity | — | — | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |